Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

Edward S. Kim, MD

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.
Printer Printing...